The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE
OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP FIGI (to the nearest dollar) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
ACELYRIN COM 00445A100   6,657,458 2,695,327 SH   SOLE   2,695,327 0 0
ADAGENE ADS 005329107   5,815,447 3,825,952 SH   SOLE   3,825,952 0 0
AKERO THERAPEUTICS COM 00973Y108   211,871,875 5,233,989 SH   SOLE   5,233,989 0 0
ALIGNMENT HEALTHCARE COM 01625V104   1,135,695,674 60,993,323 SH   SOLE   60,993,323 0 0
ALKAMI COM 01644J108   253,189,598 9,645,318 SH   SOLE   9,645,318 0 0
CENTESSA PHARMACEUTICALS ADS 152309100   139,224,543 9,681,818 SH   SOLE   9,681,818 0 0
DLOCAL CL A G29018101   532,981,836 63,906,695 SH   SOLE   63,906,695 0 0
EUROPEAN WAX CENTER CL A 29882P106   51,786,443 13,110,492 SH   SOLE   13,110,492 0 0
GROVE COLLABORATIVE CL A 39957D201   3,341,060 2,474,859 SH   SOLE   2,474,859 0 0
IMMUNOCORE ADS 45258D105   37,434,164 1,261,684 SH   SOLE   1,261,684 0 0
PHARVARIS COM N69605108   118,240,656 7,531,252 SH   SOLE   7,531,252 0 0
RISKIFIED CL A M8216R109   24,601,491 5,324,998 SH   SOLE   5,324,998 0 0
ROYALTY PHARMA CL A G7709Q104   46,695,000 1,500,000 SH   SOLE   1,500,000 0 0
WISH CL A 21077C305   4,255,120 609,616 SH   SOLE   609,616 0 0
XP, INC CL A G98239109   407,243,829 29,617,733 SH   SOLE   29,617,733 0 0